Ms. Wang is a counsel at Haiwen & Partners. Ms. Wang's practice focuses on corporate M&A, private equity, capital markets, and general corporate matters. She is experienced in advising various Chinese enterprises, multinational corporations, private equity firms, and other strategic and financial investors on cross-border M&A and private equity transactions. Her expertise covers various sectors, including healthcare, artificial intelligence, TMT, and cross-border e-commerce.
Ms. Wang joined Haiwen & Partners in 2020. Prior to joining Haiwen, Ms. Wang had worked at Zhong Lun Law Firm and Han Kun Law Offices for several years.
Corporate M&A
Advised institutional clients on equity and asset acquisitions, including representing Warburg Pincus in its acquisition of equity in ZSM Healthcare; Hillhouse in multiple control acquisitions; Guoxin Group in its acquisition of pharmaceutical companies such as Chia Tai Qingdao Pharmaceutical; Kangrun Biotech in acquisition of an innovative vaccine company; and A-share listed company Imeik in its acquisitions of several medical device and pharmaceutical R&D companies.
Advised on corporate divestitures, including representing minority shareholders in the sale of minority stakes in Lavande Hotels, Xana Hotelle, and James Joyce Coffetel to Jinjiang Hotels, as well as the sale of certain project assets by Huacheng Gas.
Participated in the privatization of overseas-listed companies such as Ruhnn Holding, represented Genor Biopharma in its merger and listing with EOC Pharma, and advised on various transactions involving acquisition of control over listed companies.
Private Equity and Venture Capital
Represented numerous USD and RMB investment funds in investments across TMT, healthcare, artificial intelligence, and other emerging sectors. These engagements encompass offshore and onshore structures, financial and strategic investments, as well as private equity and early-stage venture investments. Clients served include Hongshan, Warburg Pincus, CDH Investments, L Catterton, Hillhouse, Alibaba, Ant Group, Meituan, SAIF Partners, Tianyi Capital, IDG Capital, Gaorong Capital, Source Code Capital, Oriza Holdings, Mingshi Capital, Shangcheng Capital, CCB International, US-China Green Fund, Sinopec Enze Fund, and CICC Capital.
Represented both companies and investors in the private financings of numerous well-known enterprises, including SheIn, Pony.ai, Ant Group, GrabTaxi, Zhipu AI, Biren Technology, Mobvoi, Hyperparameters, Kayou, Full Truck Alliance, Hive Box, among others.
Securities Offering
Participated in the overseas listing projects of multiple Chinese companies, including Genor Biopharma, Mobvoi, Xingyun Group, Nanofilm Technologies, and Pony.ai.
General Corporate
Provides ongoing advice on general corporate matters for companies across diverse industries, including TMT, biotech, healthcare, retail and consumer products, AI, fintech, mobility, and semiconductors.
Ms. Wang received her LL.B. degree from China University of Political Science and Law in 2016 and her LL.M. degree from the National University of Singapore in 2017.
Ms. Wang's native language is Mandarin Chinese and she is fluent in English.
Beijing ICP No. 05019364-1 Beijing Public Network Security 110105011258
